Kingworld Medicines Group Limited (HKG:1110)
Hong Kong · Delayed Price · Currency is HKD 0.4050
+0.0050 (1.25%)
Sep 14, 2026, 11:51 AM HKT
Kingworld Medicines Group Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 787.87 | 917.34 | 1,061 | 1,079 | 957.7 | 847.39 |
Revenue Growth | -14.11% | -13.55% | -1.63% | 12.63% | 13.02% | 13.69% |
Gross Profit Gross Profit Growth | 240.04 | 247.91 | 270.45 | 280.67 | 277.63 | 263.6 |
Operating Income Operating Income Growth | 58.34 | 56.7 | 93.16 | 78.68 | 80.34 | 71.24 |
Net Income Net Income Growth | 11.47 | 11.28 | 41.56 | 38.1 | 22.74 | 30.32 |
Earnings Per Share EPS Growth | 0.02 | 0.02 | 0.07 | 0.06 | 0.04 | 0.05 |
EPS Growth | 0.90% | -73.33% | 12.06% | 71.79% | -25.02% | 162.17% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Manufacturing and Sales of Electrotherapeutic and Physiotherapeutic Devices and General Medical Examination Devices - PRC Manufacturing and Sales of Electrotherapeutic and Physiotherapeutic Devices and General Medical Examination Devices - PRC Growth | 259.06 | 248.28 | 240.94 | 268.77 | 319.96 |
Distribution Sales of Pharmaceutical and Healthcare Products - Hong Kong Distribution Sales of Pharmaceutical and Healthcare Products - Hong Kong Growth | 15.22 | 21.32 | 55.24 | 56.93 | 46.01 |
Distribution Sales of Pharmaceutical and Healthcare Products - PRC Distribution Sales of Pharmaceutical and Healthcare Products - PRC Growth | 753.35 | 919.16 | 899.85 | 734.63 | 563.12 |
Inter-Segment Inter-Segment Growth | -2.48 | -4.75 | -1.83 | -8.99 | -7.3 |
Elimination of Group's Share of Revenue of Joint Venture Elimination of Group's Share of Revenue of Joint Venture Growth | -107.82 | -122.91 | -115.54 | -93.65 | -74.4 |
Total Total Growth | 917.34 | 1,061 | 1,079 | 957.7 | 847.39 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 188.38 | 274.59 | 249.6 | 194.03 | 256.17 | 198.41 |
Total Debt Total Debt Growth | 438.13 | 433.87 | 402.44 | 354.43 | 290.68 | 238.96 |
Net Cash (Debt) Net Cash Growth | -249.74 | -159.28 | -152.84 | -160.4 | -34.51 | -40.55 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -0.42 | -0.27 | -0.27 | -0.27 | -0.06 | -0.07 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | - | 84.56 | 135.82 | 42.28 | 186.55 | 81.2 |
Capital Expenditures CapEx Growth | - | -29.64 | -41.09 | -105.54 | -93.51 | -58.32 |
Free Cash Flow Free Cash Flow Growth | - | 54.92 | 94.73 | -63.25 | 93.04 | 22.88 |
Free Cash Flow Growth | - | -42.03% | - | - | 306.62% | -79.87% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 30.47% | 27.02% | 25.49% | 26.02% | 28.99% | 31.11% |
Operating Margin | 7.41% | 6.18% | 8.78% | 7.29% | 8.39% | 8.41% |
Pretax Margin | 7.52% | 6.26% | 9.00% | 8.70% | 7.06% | 8.19% |
Profit Margin | 1.46% | 1.23% | 3.92% | 3.53% | 2.38% | 3.58% |
FCF Margin | - | 5.99% | 8.93% | -5.86% | 9.71% | 2.70% |
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.030 | 0.031 | 0.022 | 0.019 |
Dividend Per Share Growth | -2.87% | 40.74% | 11.79% | 254.55% |
Dividend Yield | 7.36% | 6.02% | 3.35% | 3.84% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 17.84 | 24.42 | 6.10 | 9.34 | 20.58 | 12.71 |
Forward PE | - | 9.16 | 9.16 | 9.16 | 9.16 | 9.16 |
P/FCF Ratio | - | 5.02 | 2.68 | - | 5.03 | 16.85 |
PS Ratio | 0.26 | 0.30 | 0.24 | 0.33 | 0.49 | 0.46 |